13 Results for "

wild-type Abl kinases inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "wild-type Abl kinases inhibitor" in MCE Product Catalog:

Cat. No.: HY-12083
CAS No.: 875634-01-8
Target:  

Bcr-Abl

Research Areas:  

Cancer

PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-15814
CAS No.: 1258391-13-7
Purity:  99.94%
Research Areas:  

Cancer

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .
loading...
    loading...
Cat. No.: HY-164393
CAS No.: 1035199-04-2
Target:  

JAK Bcr-Abl Apoptosis

Research Areas:  

Cancer

ON044580 is a non–ATP-competitive JAK2 and BCR-ABL kinases inhibitor. ON044580 inhibits wild-type (WT) and V617F mutant JAK2 with IC50 values of 1.23 μM, 1.09 μM, respectively. ON044580 also inhibits both WT and T315I mutant BCR-ABL kinases., ON044580 blocks the IL-3–mediated phosphorylation of JAK2 and STAT5, induces apoptosis in Imatinib (HY-15463)-resistant chronic myeloid leukemia (CML). ON044580 can be used for the study of CML, myelodysplasia (MDS) and other myeloproliferative neoplasms .
loading...
    loading...
Cat. No.: HY-123450
CAS No.: 1257628-57-1
Purity:  99.60%
Target:  

Bcr-Abl Apoptosis PDGFR

Research Areas:  

Cancer

S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-10364
CAS No.: 926922-16-9
Target:  

Bcr-Abl

Research Areas:  

Cancer

AP24163 is a BCR-ABL kinase inhibitor. AP24163 inhibits wild-type (native) BCR-ABL and BCR-ABL-T315I with IC50 values of 7 nM and 511 nM, respectively. AP24163 can be used in the research of chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-164469
CAS No.: 2479290-65-6
Target:  

Bcr-Abl Apoptosis STAT

Research Areas:  

Cancer

CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC50 values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-183909
CAS No.: 2097512-73-5
Target:  

FGFR

Research Areas:  

Others

EphB1-IN-2 is a mutant-selective kinase inhibitor of ABL and FGFR4, with an IC50 of 14 nM against ABL G321C mutant and 163 nM against FGFR4 G556C mutant. EphB1-IN-2 shows selectively over wild-type ABL and FGFR4 .
loading...
    loading...
Cat. No.: HY-108704
CAS No.: 1388710-60-8
Target:  

Bcr-Abl

Research Areas:  

Cancer

CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities . CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-162698
CAS No.: 1927930-61-7
Target:  

Thymidylate Synthase

Research Areas:  

Cancer

JMF4073 is a thymidylate (TMP) and cytidylate (CMP) kinases inhibitor with IC50s of 0.16 μM and 0.17 μM, respectively. JMF4073 eliminates wild-type (WT)-Bcr-Abl-transformed myeloid cells in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-165532
CAS No.: 1030610-86-6
Synonyms: SGX70393
Target:  

Bcr-Abl

Research Areas:  

Cancer

SGX393 (SGX70393) is a Bcr-Abl kinase inhibitor. SGX393 binds to the active conformation of the kinase domains of both wild-type and T315I mutant Bcr-Abl, thereby inhibiting kinase activity. SGX393 exhibits antiproliferative effects in cells expressing wild-type or T315I mutant Bcr-Abl, and suppresses T315I-driven tumor growth. SGX393 can be used for the research of chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-182792
CAS No.: 2412966-86-8
Synonyms: TERN-701
Target:  

Bcr-Abl

Research Areas:  

Cancer

Embibatinib (TERN-701) is an orally active and allosteric BCR-ABL1 tyrosine kinase inhibitor targeting the myristoyl pocket. Embibatinib exhibits an IC50 of 0.38 nM against ABL1 wild-type enzyme. Embibatinib can be used for the study of chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-184100S
CAS No.: 2767305-95-1
Synonyms: Relcobatinibum
Relcobatinib (Relcobatinibum) is a ABL1 kinase inhibitor with an IC50 of 12.7 nM against wild-type ABL1 and an IC50 of 43.5 nM against the ABL1 T315I mutant. Relcobatinib inhibits the phosphorylation of CRKL. Relcobatinib exhibits anticancer activity against chronic myeloid leukemia. Relcobatinib can be used in studies related to chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-187987
CAS No.: 2240190-29-6
Target:  

Bcr-Abl

Research Areas:  

Cancer

Meribatinib (compound 17) is a potent allosteric inhibitor of Bcr-Abl kinase. Meribatinib binds to the myristoyl binding pocket of the Bcr-Abl protein, locking the kinase domain in an inactive state. Meribatinib can be used for research on chronic myeloid leukemia .
loading...
    loading...
  • 1